title: [Influence of ferulic acid on the pain-depression dyad induced by reserpine].
abstract: This study is to offer a clinical pain-depression dyad therapy of ferulic acid, the pain-depression dyad induced by reserpine was established and the dose-effect relationship of ferulic acid on ameliorating pain-depression dyad was explored. Mice were randomly divided into control group, reserpine + vechile and reserpine + ferulic acid (5, 10, 20, 40 and 80 mg x kg(-1)) groups. The reserpine treated mice were tested with thermal hyperalgesia, mechanicial allodynia and forced swimming tests, and the SOD and NO levels of hippocampus and frontal cortex were measured. Moreover, the HPLC-ECD was used to detect the changes of central monoamines concentrations. Compared with control group, reserpine can induce a significant decrease in the nociceptive threshold and increase in the immobility time of the forced swimming test. The results suggested that reserpine significantly increased the level of nitrite in hippocampus and frontal cortex and reduced the levels of SOD, 5-HT and NE in these two brain regions. However, these indexes can be a dose-dependently reversed by ferulic acid (5, 10, 20, 40 and 80 mg x kg(-1)). Ferulic acid can reverse pain-depression dyad, especially at the dose of 80 mg x kg(-1). In addition, it can influence oxidative stress and monoamine level.
authors.affiliation: College of Pharmacy, Wenzhou Medical College, Wenzhou 325035, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Qian-Dong
authors.initials: QD
authors.lastname: Wang
authors.forename: Hua-Meng
authors.initials: HM
authors.lastname: Shi
authors.forename: Jian-Chun
authors.initials: JC
authors.lastname: Pan
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003373:Coumaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D003863:Depression / Q000139:chemically induced / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005625:Frontal Lobe / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism; D006930:Hyperalgesia / Q000503:physiopathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010146:Pain / Q000139:chemically induced / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology*; D010147:Pain Measurement; D011897:Random Allocation; D012110:Reserpine / Q000009:adverse effects; D012701:Serotonin / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013550:Swimming / Q000502:physiology
chemical_list: D000928:Antidepressive Agents; D003373:Coumaric Acids; D009569:Nitric Oxide; D012701:Serotonin; D012110:Reserpine; C004999:ferulic acid; D013482:Superoxide Dismutase; D004298:Dopamine; D009638:Norepinephrine